Paper Details

  1. Home
  2. Paper Details

A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.

Author: , AndreonePietro, BeuersUlrich, BowlusChristopher, DrenthJoost P H, FloreaniAnnarosa, HansenBettina, HirschfieldGideon M, HohenesterSimon, Hooshmand-RadRoya, InvernizziPietro, JonesDavid E, KowdleyKris V, LindorKeith D, LuketicVelimir, MacConellLeigh, MarmonTonya, MarschallHanns-Ulrich, MazzellaGiuseppe, NevensFrederik, PencekRichard, PockrosPaul J, PruzanskiMark, RegulaJaroslaw, ShahHemant, ShapiroDavid, SheeronShawn, ShiffmanMitchell, StrasserSimone I, TraunerMichael, VargasVictor, VincentCatherine, van ErpecumKarel J

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study discusses the potential benefit of obeticholic acid, a farnesoid X receptor agonist, for patients with primary biliary cholangitis (PBC). The study emphasizes the importance of managing PBC due to the potential for progression to cirrhosis and death.
Paper Details　
Original Abstract of the Article :
Primary biliary cholangitis (formerly called primary biliary cirrhosis) can progress to cirrhosis and death despite ursodiol therapy. Alkaline phosphatase and bilirubin levels correlate with the risk of liver transplantation or death. Obeticholic acid, a farnesoid X receptor agonist, has shown poten...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa1509840

データ提供：米国国立医学図書館（NLM）

A Closer Look at Obeticholic Acid for Primary Biliary Cholangitis

The world of [hepatology] is always searching for new ways to treat [primary biliary cholangitis], a condition that can lead to [cirrhosis] and even [death]. This study explores the potential of [obeticholic acid], a [farnesoid X receptor agonist], as a treatment option for this challenging disease.

The researchers used a [placebo-controlled trial] to assess the effectiveness of [obeticholic acid] in patients already taking [ursodiol]. They found that [obeticholic acid] could potentially improve [alkaline phosphatase] and [bilirubin] levels, which are important markers for the severity of [primary biliary cholangitis]. These findings suggest that [obeticholic acid] might be a valuable tool in managing [primary biliary cholangitis] and slowing its progression.

Promising Signs for a New Treatment

The study's results suggest that [obeticholic acid] could offer hope for [primary biliary cholangitis] patients. The fact that it might be able to improve [alkaline phosphatase] and [bilirubin] levels, two key indicators of the disease's severity, is a significant discovery. While further research is necessary to confirm its long-term efficacy and safety, this study provides a promising starting point for developing new and effective treatments for this challenging condition.

Navigating the Desert of Liver Disease

If you're facing the challenges of [primary biliary cholangitis], it's important to stay informed about the latest advancements in treatment. While [obeticholic acid] shows promise, it's crucial to consult with your healthcare provider to determine the best course of action for your individual situation.

Dr.Camel's Conclusion

This study reminds us that the desert of liver disease is vast and complex, but even the smallest oasis can offer a glimmer of hope. The potential benefits of [obeticholic acid] for [primary biliary cholangitis] are exciting and warrant further exploration. As a wise camel, I encourage you to keep seeking knowledge and consult with your healthcare provider for personalized guidance.

Date :
  1. Date Completed 2016-08-23
  2. Date Revised 2022-04-10
Further Info :

Pubmed ID

27532829

DOI: Digital Object Identifier

10.1056/NEJMoa1509840

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.